Xenon (XENE) Director Steven Gannon Sells 10,000 Shares

What Happened
Steven Gannon, a director of Xenon Pharmaceuticals (XENE), sold 10,000 shares in an open-market transaction on August 11, 2026. The reported weighted-average sale price was $64.06 per share, for total proceeds of approximately $640,550. This was a sale (disposition) of shares rather than a purchase or option exercise.

Key Details

• Transaction date: 2026-08-11; Form 4 filed 2026-08-13 (Accession: 0001193125-26-349351).
• Shares sold: 10,000; weighted-average price reported: $64.06; total proceeds ≈ $640,550.
• Price range: $64.0517 to $64.078 (sold in multiple trades; reporting person can provide per-price breakdown on request).
• Transaction type: Open-market sale (SEC code S).
• Shares owned after transaction: Not specified in the summary data provided — see the Form 4 filing for post-transaction holdings.
• Filing timeliness: Filed within the typical two-business-day window after the transaction.

Context

• Sales by directors are often routine (portfolio-management or liquidity reasons) and, by themselves, do not necessarily indicate a change in company outlook.
• No option exercise, award, gift, or 10b5-1 plan was noted in the provided details.
• Retail investors should consider this data point alongside other insider activity, company fundamentals, and market conditions before drawing investment conclusions.